New HIV Vaccine may Boost Patients’ Immune System, Improves Effects of Medications

When HIV-positive patients are given the vaccine that contains Tat proteins, it increases the immune cells and enhances the effect of antiretroviral drugs.

A HIV vaccine containing protein necessary for virus replication can boost immune system of a HIV- infected patient and increase the effect of antiretroviral drugs.

"We prove for the first time that antiretroviral therapy may be intensified by a vaccine," said lead researcher Barbara Ensoli from the Italian National AIDS Center at the Istituto Superiore di Sanita in Rome, Italy.

About AIDS/HIV - Prevention And Transmission
Encyclopedia section of medindia explains in brief about the prevention for AIDS/HIV

"These results open new scenarios to investigate, namely whether this vaccine may help with virus control where patients have low adherence to antiretroviral therapy, simplify treatment, and reduce transmission of the disease," Ensol noted.

When people are first diagnosed with HIV they are put on antiretroviral drugs, also known as highly active antiretroviral therapy (HAART). These drugs can stop the virus reproducing almost completely.

When taking HAART, however, it is known that the virus can still replicate at low levels and accumulate in a latent form in what are called "reservoirs".

Complex Protein may Help HIV Vaccine Development
Scientists at Duke University have taken aim at what may be an Achilles' heel of the HIV virus.

The new study has now found that a vaccine that targets the viral protein "Tat", which is produced early on in HIV infection, can increase effectiveness of these drugs used in current HIV treatment.

For the study, the researchers conducted a Phase II clinical trial that injected 168 HIV-infected patients with the vaccine that contained either 7.5 micrograms or 30 micrograms of the Tat protein.

Scientific Discovery Offers Hope for HIV Vaccine Development
In a scientific discovery that has significant implications for HIV vaccine development, collaborators have uncovered novel properties of special HIV antibodies.

For both doses, the participants received the vaccine once a month over the course of either three or five months. The patients also continued on HAART treatment.

Patients were followed for three years (144 weeks). It was found that the vaccine induced production of anti-Tat antibodies.

New Insights into HIV Vaccine
A potential HIV vaccine showed promise four years ago against the virus that causes AIDS, but it fell short of providing the broad protection necessary to stem the spread of disease.

A significant growth of CD4+ T cells was also seen, which is a sign of the immune system’s strength.

There was also an increase in the T, B and other immune cells. The biggest response was seen among those who received the vaccine with 30 micrograms of Tat over the course of three months. These effects were found to persist for all the three years.

The study was published in the open-access journal Retrovirology.

Source-Medindia